Deutsch English Français

Contact

EP2501384

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2501384

EP2501384 - METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY [Right-click to bookmark this link]
Status	Patent maintained as amended Status updated on 29.09.2023 Database last updated on 03.04.2025
Former	The patent has been granted Status updated on 16.05.2018
Most recent event Tooltip	29.09.2023	Patent maintained (B2 publication)	published on 01.11.2023 [2023/44]
Applicant(s)	For all designated states Novartis AG Lichtstrasse 35 4056 Basel / CH
	[2023/44]
Former [2012/39]	For all designated states Novartis AG Lichtstrasse 35 4056 Basel / CH
Inventor(s)	01 / GALLAGHER, Neil Novartis Pharma AG Postfach CH-4002 Basel / CH
	02 / YIN, Ophelia 66 Henning Terrace Denville New Jersey 07834 / US
	[2012/39]
Representative(s)	Aera A/S Niels Hemmingsens Gade 10, 5th Floor 1153 Copenhagen K / DK
	[2023/44]
Former [2016/07]	Roth, Peter Richard Novartis Pharma AG Patent Department 4002 Basel / CH
Former [2012/39]	Roth, Peter Richard Novartis Pharma AG Patent Department 4002 Basel / CH
Application number, filing date	10781781.9	17.11.2010
	[2016/07]
	WO2010US56926
Priority number, date	US20090261812P	17.11.2009 Original published format: US 261812 P
	[2012/39]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2011062927
	Date:	26.05.2011
	Language:	EN
	[2011/21]
	Type:	A1 Application with search report
	No.:	EP2501384
	Date:	26.09.2012
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 26.05.2011 takes the place of the publication of the European patent application.
	[2012/39]
	Type:	B1 Patent specification
	No.:	EP2501384
	Date:	17.02.2016
	Language:	EN
	[2016/07]
	Type:	B2 New European patent specification
	No.:	EP2501384
	Date:	01.11.2023
	Language:	EN
	[2023/44]
Search report(s)	International search report - published on:	EP	26.05.2011
Classification	IPC:	A61K31/506, A61P35/00, A61K9/00, C07D239/69	[2015/27]
	CPC:	A61K31/506 (EP,KR,RU,US); A61K9/0095 (EP,KR,US); A61P11/00 (EP); A61P11/06 (EP); A61P17/00 (EP); A61P17/06 (EP); (+) A61P19/02 (EP); A61P19/04 (EP); A61P25/00 (EP); A61P25/28 (EP); A61P29/00 (EP); A61P35/00 (EP); A61P35/02 (EP); A61P37/06 (EP); A61P43/00 (EP); A61P9/12 (EP); C07D239/69 (EP,KR,US); A61K31/505 (RU) (-)
	Former IPC [2012/39]	A61K31/506, A61P35/00, A61K9/00
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2012/39]
Extension states	BA	18.06.2012
	ME	18.06.2012
Title	German:	VERFAHREN ZUR BEHANDLUNG VON DURCH BCR-ABL, C-KIT, DDR1, DDR2 ODER PDGF-R-KINASEAKTIVITÄT VERMITTELTEN PROLIFERATIVEN ERKRANKUNGEN UND ANDEREN KRANKHEITSZUSTÄNDEN	[2012/39]
	English:	METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY	[2012/39]
	French:	MÉTHODE DE TRAITEMENT DE TROUBLES PROLIFÉRATIFS ET D'AUTRES AFFECTIONS PATHOLOGIQUES MÉDIÉS PAR BCR-ABL, C-KIT, DDR1, DDR2 OU L'ACTIVITÉ KINASE DU PDGF-R	[2012/39]
Entry into regional phase	18.06.2012	National basic fee paid
	18.06.2012	Designation fee(s) paid
	18.06.2012	Examination fee paid
Examination procedure	18.06.2012	Examination requested [2012/39]
	17.01.2013	Amendment by applicant (claims and/or description)
	10.07.2013	Despatch of a communication from the examining division (Time limit: M06)
	20.01.2014	Reply to a communication from the examining division
	02.04.2014	Observations by third parties
	08.04.2014	Observations by third parties
	19.09.2014	Despatch of a communication from the examining division (Time limit: M04)
	05.12.2014	Reply to a communication from the examining division
	13.08.2015	Communication of intention to grant the patent
	10.12.2015	Fee for grant paid
	10.12.2015	Fee for publishing/printing paid
	10.12.2015	Receipt of the translation of the claim(s)
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 10.07.2013
Opposition(s)	Opponent(s)	01 14.11.2016 17.11.2016 ADMISSIBLE Fresenius Kabi Deutschland GmbH Else-Kröner-Str. 1 61352 Bad Homburg / DE Opponent's representative Fresenius Kabi Deutschland GmbH, et al, et al Patent Department Pharmaceuticals Division Borkenberg 14 61440 Oberursel / DE
		02 17.11.2016 23.11.2016 ADMISSIBLE Hamm&Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB, et al, et al Jungfernstieg 38 20354 Hamburg / DE
		03 17.11.2016 23.11.2016 ADMISSIBLE TEVA PHARMACEUTICAL INDUSTRIES, LTD. 124 Dvora HaNevi'a St. 6944020 Tel Aviv / IL Opponent's representative D Young & Co LLP, et al, et al 3 Noble Street London EC2V 7BQ / GB
		04 17.11.2016 23.11.2016 ADMISSIBLE Intas Pharmaceuticals Ltd. 2nd Floor Chinubhai Centre Ashram Road Ahmedabad 380009 GUJ / IN Opponent's representative Isarpatent, et al, et al Patent- und Rechtsanwälte Barth Charles Hassa Peckmann & Partner mbB Friedrichstrasse 31 80801 München / DE
		05 17.11.2016 23.11.2016 ADMISSIBLE Generics (U.K.) Limited Station Close Potters Bar Hertfordshire EN6 1TL / GB Opponent's representative Elkington and Fife LLP, et al, et al Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		[N/P]
	Former [2021/47]
	Opponent(s)	01 14.11.2016 17.11.2016 ADMISSIBLE Fresenius Kabi Deutschland GmbH Else-Kröner-Str. 1 61352 Bad Homburg / DE Opponent's representative Fresenius Kabi Deutschland GmbH, et al, et al Patent Department Pharmaceuticals Division Borkenberg 14 61440 Oberursel / DE
		02 17.11.2016 23.11.2016 ADMISSIBLE Hamm&Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB, et al, et al Jungfernstieg 38 20354 Hamburg / DE
		03 17.11.2016 23.11.2016 ADMISSIBLE TEVA PHARMACEUTICAL INDUSTRIES, LTD. 124 Dvora HaNevi'a St. 6944020 Tel Aviv / IL Opponent's representative D Young & Co LLP, et al, et al 120 Holborn London EC1N 2DY / GB
		04 17.11.2016 23.11.2016 ADMISSIBLE Intas Pharmaceuticals Ltd. 2nd Floor Chinubhai Centre Ashram Road Ahmedabad 380009 GUJ / IN Opponent's representative Isarpatent, et al, et al Patent- und Rechtsanwälte Barth Charles Hassa Peckmann & Partner mbB Friedrichstrasse 31 80801 München / DE
		05 17.11.2016 23.11.2016 ADMISSIBLE Generics (U.K.) Limited Station Close Potters Bar Hertfordshire EN6 1TL / GB Opponent's representative Elkington and Fife LLP, et al, et al Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
	Former [2020/49]
	Opponent(s)	01 14.11.2016 17.11.2016 ADMISSIBLE Fresenius Kabi Deutschland GmbH Else-Kröner-Str. 1 61352 Bad Homburg / DE Opponent's representative Fresenius Kabi Deutschland GmbH, et al, et al Patent Department Pharmaceuticals Division Borkenberg 14 61440 Oberursel / DE
		02 17.11.2016 23.11.2016 ADMISSIBLE Hamm&Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB, et al, et al Jungfernstieg 38 20354 Hamburg / DE
		03 17.11.2016 23.11.2016 ADMISSIBLE Teva Pharmaceutical Industries Ltd 5 Basel Street P.O. Box 3190 49131 Petah Tiqva / IL Opponent's representative D Young & Co LLP, et al, et al 120 Holborn London EC1N 2DY / GB
		04 17.11.2016 23.11.2016 ADMISSIBLE Intas Pharmaceuticals Ltd. 2nd Floor Chinubhai Centre Ashram Road Ahmedabad 380009 GUJ / IN Opponent's representative Isarpatent, et al, et al Patent- und Rechtsanwälte Behnisch Barth Charles Hassa Peckmann & Partner mbB Friedrichstrasse 31 80801 München / DE
		05 17.11.2016 23.11.2016 ADMISSIBLE Generics (U.K.) Limited Station Close Potters Bar Hertfordshire EN6 1TL / GB Opponent's representative Elkington and Fife LLP, et al, et al Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
	Former [2018/52]
	Opponent(s)	01 14.11.2016 17.11.2016 ADMISSIBLE Fresenius Kabi Deutschland GmbH Else-Kröner-Str. 1 61352 Bad Homburg / DE Opponent's representative Fresenius Kabi Deutschland GmbH, et al, et al Patent Department Pharmaceuticals Division Borkenberg 14 61440 Oberursel / DE
		02 17.11.2016 23.11.2016 ADMISSIBLE Hamm&Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB, et al, et al Jungfernstieg 38 20354 Hamburg / DE
		03 17.11.2016 23.11.2016 ADMISSIBLE Teva Pharmaceutical Industries Ltd 5 Basel Street P.O. Box 3190 49131 Petah Tiqva / IL Opponent's representative D Young & Co LLP, et al, et al 120 Holborn London EC1N 2DY / GB
		04 17.11.2016 23.11.2016 ADMISSIBLE Intas Pharmaceuticals Ltd. 2nd Floor Chinubhai Centre Ashram Road Ahmedabad 380009 GUJ / IN Opponent's representative Accord Healthcare, S.L.U., et al, et al World Trade Center Moll de Barcelona s/n Edifici Est, 6ª planta 08039 Barcelona / ES
		05 17.11.2016 23.11.2016 ADMISSIBLE Generics (U.K.) Limited Station Close Potters Bar Hertfordshire EN6 1TL / GB Opponent's representative Elkington & Fife LLP, et al, et al Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
	Former [2016/52]
	Opponent(s)	01 14.11.2016 17.11.2016 ADMISSIBLE Fresenius Kabi Deutschland GmbH Else-Kröner-Str. 1 61352 Bad Homburg / DE Opponent's representative Fresenius Kabi Deutschland GmbH, et al, et al Patent Department Pharmaceuticals Division Borkenberg 14 61440 Oberursel / DE
		02 17.11.2016 23.11.2016 ADMISSIBLE Hamm&Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE Opponent's representative Hamm & Wittkopp Patentanwälte PartmbB, et al, et al Jungfernstieg 38 20354 Hamburg / DE
		03 17.11.2016 23.11.2016 ADMISSIBLE Teva Pharmaceutical Industries Ltd 5 Basel Street P.O. Box 3190 49131 Petah Tiqva / IL Opponent's representative D Young & Co LLP, et al, et al 120 Holborn London EC1N 2DY / GB
		04 17.11.2016 23.11.2016 ADMISSIBLE Intas Pharmaceuticals Ltd. 2nd Floor Chinubhai Centre Ashram Road Ahmedabad 380009 GUJ / IN Opponent's representative Accord Healthcare, S.L.U., et al, et al Department: Intellectual Property Europe World Trade Center Moll de Barcelona s/n Edifici Est, 6ª planta 08039 Barcelona / ES
		05 17.11.2016 23.11.2016 ADMISSIBLE Generics (U.K.) Limited Station Close Potters Bar Hertfordshire EN6 1TL / GB Opponent's representative Cooke, Richard Spencer, et al, et al Elkington and Fife LLP Patents Department 3-4 Holborn Circus London EC1N 2HA / GB
	Former [2016/51]
	Opponent(s)	01 14.11.2016 17.11.2016 ADMISSIBLE Fresenius Kabi Deutschland GmbH Else-Kröner-Str. 1 61352 Bad Homburg / DE Opponent's representative Fresenius Kabi Deutschland GmbH, et al, et al Patent Department Pharmaceuticals Division Borkenberg 14 61440 Oberursel / DE
	09.01.2017	Invitation to proprietor to file observations on the notice of opposition
	18.05.2017	Reply of patent proprietor to notice(s) of opposition
	24.04.2018	Date of oral proceedings
	17.05.2018	Despatch of minutes of oral proceedings
	17.05.2018	Despatch of communication that the patent will be revoked
	23.01.2023	Despatch of a communication from the opposition division (Time limit: M02)
	19.05.2023	Despatch of interlocutory decision in opposition
	29.05.2023	Legal effect of interlocutory decision in opposition
	18.09.2023	Despatch of communication that the patent will be maintained as amended
Appeal following opposition	09.07.2018	Appeal received No. T1806/18
	27.09.2018	Statement of grounds filed
	21.10.2021	Result of appeal procedure: maintenance in amended form
	25.11.2022	Despatch of the decision of the Board of Appeal
	21.10.2021	Date of oral proceedings
Fees paid	Renewal fee
	13.11.2012	Renewal fee patent year 03
	18.11.2013	Renewal fee patent year 04
	10.11.2014	Renewal fee patent year 05
	10.11.2015	Renewal fee patent year 06
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	SM	08.06.2018
	MC	30.11.2018
	[2019/33]
Former [2018/40]	SM	08.06.2018
Cited in	International search	[XI]WO2004005281 (NOVARTIS AG [CH], et al);
		[XI]WO2006119154 (NOVARTIS AG [CH], et al);
	by applicant	WO2004005281
		EP1533304
		WO2007015871
		WO2007015870
		WO2008037716
	Opposition	WO2008037716
		WO2004005281
		WO2006119154

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.32; 35p